Haemostasis and oral contraceptives.

Area of Science:

• Reproductive endocrinology
• Hematology
• Thrombosis research

Background:

• Oral contraceptives (OCs) are widely used by women of reproductive age.
• Concerns exist regarding the potential impact of OCs on hemostasis and thrombotic risk.
• Previous studies have yielded conflicting results on OC-induced changes in coagulation parameters.

Purpose of the Study:

• To investigate the effects of different oral contraceptives on selected hemostasis parameters.
• To determine if OC use leads to a state of hypercoagulability.
• To explore correlations between clinical parameters and hemostasis data in OC users.

Main Methods:

• Assay of 11 hemostasis parameters in 131 women using oral contraceptives and 36 controls.
• Analysis included fibrinogen, antithrombin III, Protein C, plasminogen, fibronectin, and others.
• Canonical correlation analysis was performed to link clinical and hemostasis data.

Main Results:

• No significant differences in fibrinogen, antithrombin III, prekallikrein, alpha 2 antiplasmin, fibrinopeptide A, platelet factor 4, or beta-thromboglobulin.
• Protein C and plasminogen levels were significantly higher in OC users (p<0.001, p<0.01).
• Fibronectin levels were significantly lower in OC users (p<0.05).
• Negative correlation between antithrombin III and family history of thromboembolism.
• Positive correlation between fibrinogen and fibronectin in obese OC users.

Conclusions:

• Oral contraceptive use does not appear to induce a general state of hypercoagulability.
• Observed changes in Protein C, plasminogen, and fibronectin suggest a complex but not necessarily prothrombotic hemostatic adaptation.
• Individual factors like family history and obesity may modulate hemostatic responses to OCs.